Biotech News
Cullinan Therapeutics to Participate in Upcoming Investor Conferences
Cullinan Therapeutics, Inc. (Nasdaq: CGEM; “Cullinan”), a clinical-stage biopharmaceutical company accelerating potential first- or best-in-class, disease-modifying T cell engagers in autoimmune diseases and cancer, today announced that members of its management team will participate in fireside chats at the following upcoming investor conferences:
